Pretransplant IFNgamma production by cytomegalovirus-specific CD8+ T cells informs the risk of cytomegalovirus replication after solid organ transplantation

Event Abstract Back to Event Pretransplant IFNgamma production by cytomegalovirus-specific CD8+ T cells informs the risk of cytomegalovirus replication after solid organ transplantation Sara Cantisán1*, Julián Torre-Cisneros1, 2, Rosario Lara1, Javier Redel3, Alberto Rodriguez-Benot4, Juan Gutiérrez-Aroca5, Aurora Páez-Vega1, Antonio Rivero1, 2, Miguel Montejo6 and Rafael Solana7 1 Maimonides Institute for Research in Biomedicine of Cordoba/Reina Sofia Hospital/University of Cordoba, Immunity and infection, Spain 2 Reina Sofia University Hospital, Infectious Diseases Unit, Spain 3 Reina Sofia University Hospital, Neumology Department, Spain 4 Reina Sofia University Hospital, Nephrology Department, Spain 5 Reina Sofia University Hospital, Microbiology Department, Spain 6 Cruces Hospital, Infectious Diseases Unit, Spain 7 Reina Sofia University Hospital, Immunology Department, Spain 1. PURPOSE/OBJECTIVES In this prospective study we analyzed pretransplant IFNgamma secretion by cytomegalovirus (CMV)-specific CD8+ T cells to assess its possible utility in determining the risk of CMV replication after solid organ transplantation. 2. MATERIAL AND METHODS This longitudinal study was carried out in two centers of the REIPI network (Reina Sofia Hospital, Cordoba, and Cruces Hospital, Bilbao, Spain). Fifty-five adult patients awaiting lung or kidney transplantation were evaluable for the study. IFNgamma production by CMV-specific CD8+ T-cells was assessed pretransplant using the QuantiFERON®-CMV (QF-CMV) assay. A result was considered “reactive” when the CMV antigen response minus the negative control response was greater than 0.2 IU/mL of IFNgamma. CMV load was monitored for 24 months after transplantation. 3. RESULTS All CMV-seronegative recipients were QF-CMV “non-reactive” (11/11). However, in CMV-seropositive recipients, R(+), 68.2% (30/44) were QF-CMV “reactive” and 31.8% (14/44) were QF-CMV "non-reactive". Within R(+) recipients, 50% (7/14) of R(+)QF-CMV "non-reactive" recipients developed CMV replication after transplantation, whereas the virus replicated only in 13.3% (4/30) of R(+)QF-CMV "reactive" patients. In kidney transplant recipients, CMV replicated earlier post-transplant, reached a higher peak CMV load, replication episodes were longer and the frequency of CMV disease was higher in R(+)QF-CMV "non-reactive" than in R(+)QF-CMV "reactive" patients. 4. CONCLUSIONS One third of R(+) transplant candidates are QuantiFERON-CMV “non-reactive” and they are at higher risk for CMV replication after transplantation. Thus, determining pretransplant IFNgamma production by CMV-specific CD8+ T cells may be useful in predicting the risk of post-transplant CMV replication in solid-organ transplantation and it might aid in reclassifying transplant candidates. Acknowledgements This work was supported by the Spanish Ministry of Science and Innovation and the Carlos III Health Institute (grant numbers FIS09/0723 to R.S., FIS08/0336 to J.T.C.), and cofinanced by the European Regional Development Fund and the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008). We are grateful to Mr. George Dragovic and Cellestis, a QIAGEN company, for providing the QuantiFERON-CMV kits. Keywords: Cytomegalovirus, solid organ transplantation, CD8+ T cells, Interferon-gamma, Virus Replication Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Translational immunology and immune intervention Citation: Cantisán S, Torre-Cisneros J, Lara R, Redel J, Rodriguez-Benot A, Gutiérrez-Aroca J, Páez-Vega A, Rivero A, Montejo M and Solana R (2013). Pretransplant IFNgamma production by cytomegalovirus-specific CD8+ T cells informs the risk of cytomegalovirus replication after solid organ transplantation. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00666 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 12 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. Sara Cantisán, Maimonides Institute for Research in Biomedicine of Cordoba/Reina Sofia Hospital/University of Cordoba, Immunity and infection, Cordoba, Spain, sacanti@hotmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Sara Cantisán Julián Torre-Cisneros Rosario Lara Javier Redel Alberto Rodriguez-Benot Juan Gutiérrez-Aroca Aurora Páez-Vega Antonio Rivero Miguel Montejo Rafael Solana Google Sara Cantisán Julián Torre-Cisneros Rosario Lara Javier Redel Alberto Rodriguez-Benot Juan Gutiérrez-Aroca Aurora Páez-Vega Antonio Rivero Miguel Montejo Rafael Solana Google Scholar Sara Cantisán Julián Torre-Cisneros Rosario Lara Javier Redel Alberto Rodriguez-Benot Juan Gutiérrez-Aroca Aurora Páez-Vega Antonio Rivero Miguel Montejo Rafael Solana PubMed Sara Cantisán Julián Torre-Cisneros Rosario Lara Javier Redel Alberto Rodriguez-Benot Juan Gutiérrez-Aroca Aurora Páez-Vega Antonio Rivero Miguel Montejo Rafael Solana Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.